Vacuolar ATPase blocker was encapsulated in the PLGA nanoparticles using the single emulsion technique. The nanoparticles were characterized by HPLC and DLS. The nanoparticle exhibited broad-spectrum antiviral activity when incubating with susceptible cells or animals.

Influenza virus is a global health concern. Every year, the influenza virus infection causes critical disease in at least three million patients and takes away half a million lives. Due to the high variability of the virus, tens of billions of US dollars are spent every year on virus diagnosis, treatment, and vaccine preparation. The virus continues on evolving and derive drug resistance. A new therapeutic approach a needed. In our technology, vacuolar ATPase blocker was encapsulated in the PLGA
nanoparticles using the single emulsion technique. After purification, the
nanoparticles were characterized by HPLC and DLS. The nanoparticles can effectively deliver the vacuolar ATPase blocker into cellular compartment, controlled release, and exhibit dose-dependent antiviral activity against the human/avian influenza virus, flavivirus, and feline coronavirus when incubating with susceptible cells or animals. The novel vacuolar ATPase-inhibiting nanoparticles are well-tolerated in cells and animals, showing promise in antiviral therapeutic design. In this host-targeted approach, no drug resistance will occur.

預防與治療流感病毒感染症、黃病毒感染症、貓冠狀病毒感染症